Topical acne treatment, RETIN-A MICRO (tretinoin) gel microsphere 0.06% from Ortho Dermatologics, is now available commercially to healthcare professionals. The gel features a microsponge delivery system technology that helps to control the release of tretinoin and improve photostability, plus a pump dispenser for controlled and consistent dosing. Clinical data provided to the U.S. Food and Drug Administration showed 98.7% (252/255) and 94% (210/224) of patients found RETIN-A-MICRO to be tolerable.
“The supplemental approval of RETIN-A MICRO gel microsphere 0.06% builds upon our heritage as a leader in developing innovative acne therapies that meet the evolving needs of our customers and their patients,” said Bill Humphries, executive vice president and group company chairman, Ortho Dermatologics (a division of Valeant). “As acne continues to be a widely prevalent skin disease, we are committed to introducing more treatment options for this large and growing patient population.”